Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Reverse share split and malaria commercialization

Af Michael FriisHead of Equities
ExpreS2ion Biotech Holding

On 16 October 2024, ExpreS2ion Biotechnologies announced that the company had signed a term sheet with Serum Institute of India Private Limited (SIIPL), a leading global vaccine manufacturer, to commercialize malaria vaccines currently in Phase I and Phase II.

On 21 October 2024, a reverse share split of the company’s shares was resolved, whereby 40 existing shares would be consolidated into 1 share, which is effective today.

In connection with these announcements, we sat down with the company’s CEO Bent Frandsen to get more flavor on the news. Hear more about the potential partner on the malaria vaccines and the next steps, as well as the rationale behind carrying out a reverse share-split in the video. 

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis 13:53, 30 October 2024.

AKTIER MED FRIIS - UGE 24 2025
13.06.2025, 12.00
Marimekko as an Investment | Consumer Goods Night June 9, 2025
12.06.2025, 11.30 Marimekko
Clas Ohlson, Audiocast, Q4'25
12.06.2025, 09.00 Clas Ohlson
Scanfil's press conference of ADCO Circuits acquisition
11.06.2025, 14.30 Scanfil
Outokumpu's Capital Markets Day 2025
11.06.2025, 12.00 Outokumpu
Vis alle videoer
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.